"We are very pleased by the participation of John Muir Physician Network Clinical Research Center," says Anna Gluskin, Generex's President and Chief Executive Officer. "We anticipate that a concentrated effort for the Treatment IND Program within centers that have an established network of patients with diabetes will serve as a good base from which the program can expand within the United States."

Under the Expanded Access Treatment IND program, Generex Oral-lyn?„? will be provided to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for the treatment of diabetes, and who are not eligible to participate in the Company's ongoing global Phase III pivotal clinical trial.

This Treatment IND is open to patients who comply with the selection criteria of the treatment protocol, including those who are taking currently approved anti-diabetic medications. There are no oral or injectable medications contraindicated for this treatment use program.

Source Generex Biotechnology Corporation